Several years ago, there was trouble in this peripherally acting mu-opioid receptor antagonist class of OIC treatments. Salix' (NASDAQ:SLXP) Relistor and Cubist's (NASDAQ:CBST) Entereg, though not approved for chronic pain patients, were causing some acute ... ...

41 people liked this